-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $260

Benzinga·01/20/2026 11:57:18
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $260.